Exploring how big-size and mid-size MedTech companies approach collaborations and partnerships with early-stage start-ups

Large companies and mid-size companies increasingly depend on external innovation to find new sources of growth of competitiveness. How do big and mid-size MedTech companies handle early-stage partnerships and investment opportunities with start-ups and academic assets? How do these companies balance between the different types of collaborations that exist? What criteria do they take account when evaluating potential partnerships? Are there differences in their approach when dealing with early-stage assets? As a result, what makes a start-up an attractive target for partnerships?

Moderator: Carole Absil, HealthTech Strategist